Found offers a genuinely broad "whole person" program — coaching, community, and multiple medication tiers — but its pricing structure across compounded, branded, and generic plans can be confusing to compare at a glance.
If you want structured behavioral coaching alongside medication, Found's model has real value. If you want a simpler, flat price focused specifically on GLP-1 treatment, Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) are more straightforward to compare.
Found was built around the idea that lasting weight loss requires more than a prescription — it pairs GLP-1 medication with health coaching, community support, and habit-tracking tools. That "whole person" philosophy differentiates it from more medication-first platforms, though it also means Found's plan structure has more moving parts to evaluate.
How Found's Program Works
Found offers several distinct plan families: a compounded GLP-1 plan (which bundles the compounded medication cost into the cycle price), a branded GLP-1 plan (which bills brand-name medication separately, through insurance or cash pay), and a non-GLP-1 generics plan for other appetite or metabolic medications. Membership costs have been reported in a range depending on the specific tier and whether you're self-pay or using insurance, with compounded plans commonly starting somewhere in the $99-$199/month range and branded plans priced differently based on insurance status.
The initial evaluation process includes a health questionnaire and provider review to determine which specific plan family fits your situation, similar to most GLP-1 telehealth platforms currently operating in this space. What differs at Found is that this evaluation also determines your tier assignment, which subsequently shapes your entire billing structure going forward, making this initial step more consequential for your total cost than at a single-tier, flat-rate provider.
Where Pricing Gets Confusing
Because Found segments its offering into multiple plan families with different billing structures, comparing your actual total cost requires understanding which specific plan you're being quoted — compounded, branded, or generic — since each bills differently. Lab testing, when required, is typically billed separately from membership as well, adding another line item to track. Patients researching Found should ask specifically which plan tier applies to their situation and what the full monthly total looks like before enrolling, rather than assuming a single advertised price applies universally.
This complexity isn't unique to Found — several multi-tier providers in this space share a similar structure — but it does mean online reviews and cost comparisons involving Found should be read carefully, since a reviewer describing "Found's price" may be referencing a different tier than the one you'd actually be assigned based on your own health profile and specific eligibility criteria.
Found's coaching and community features are a genuine differentiator for patients who want structured behavioral support alongside medication — habit tracking, an in-app community, and health-coach messaging are built into the core experience, not sold as an expensive add-on. Found also offers one of the broader medication toolkits in the space, including non-GLP-1 options for patients who aren't eligible for or don't want a GLP-1.
Understanding Found's Multi-Tier Plan Structure
Found segments its offering into multiple plan tiers — commonly a compounded medication track, a branded medication track, and non-GLP-1 options for patients who don't qualify for or prefer not to use GLP-1 medications. Each tier carries its own separate pricing and billing structure, which is a genuinely more complex setup to evaluate than a single flat-rate plan. Before enrolling, it's worth asking Found directly which specific tier you'd be assigned to based on your health profile and goals, since the tier you land in significantly affects your total monthly cost.
This tiered approach does offer real flexibility for patients whose needs might not fit a one-size-fits-all program — someone who doesn't qualify for GLP-1 medication, for instance, can still access Found's behavioral coaching and other non-GLP-1 tools through a different tier. The tradeoff is that comparing "Found's price" to a competitor requires first identifying which specific tier applies to your situation, rather than referencing a single advertised number that may not actually apply to your circumstances.
It's also worth understanding that tier assignment isn't necessarily permanent — as your health profile changes (weight-loss progress, new diagnoses, or changing insurance status), you may become eligible for a different tier over time. Confirming how Found handles these tier transitions, both clinically and financially, is a reasonable question to raise during your initial evaluation rather than assuming your starting tier will remain fixed indefinitely.
The Coaching and Community Layer
Found includes habit-tracking tools, health-coach messaging, and an in-app community as part of its core offering, positioning itself as more than a medication-delivery service. For patients who value structured behavioral support alongside medication, this can add genuine value, similar to the tradeoff discussed with other multi-service platforms in this space. As with any bundled coaching feature, the value depends heavily on whether you'll actually engage with it consistently — unused coaching features add cost without adding benefit, regardless of how well-designed the program is or how many features it includes on paper.
Community features specifically can be a meaningful source of accountability and motivation for some patients, connecting them with others working through similar goals and challenges, while other patients find community features unnecessary or prefer to keep their weight-loss journey more private. Neither preference is wrong; it's simply worth being honest with yourself about which type of patient you are before assuming the coaching and community layer justifies its portion of the overall program cost.
Where the Tradeoffs Are
Patient reviews have noted mixed experiences with cancellation processes and communication that happens primarily through in-app messaging rather than phone support. For cash-pay patients specifically, the combination of membership fees, medication costs, and separately-billed labs can add up to a less predictable total than a simpler flat-rate model.
The tiered structure itself is also worth flagging as a potential source of friction: patients who start on one tier and later need or want to move to a different tier (for example, transitioning from compounded to branded medication due to a formulary change) should confirm directly how that transition is handled, both clinically and from a billing standpoint, since it isn't always a seamless process across tiers built around fundamentally different pricing models.
Found's Clinical Team Structure
Found emphasizes a multidisciplinary care team approach, which can include physicians, registered dietitians, and health coaches working together rather than a single provider managing your entire treatment. This structure is designed to address weight management as a more holistic issue than medication alone, incorporating nutrition guidance and behavioral support alongside the prescribing relationship. For patients who want that broader team-based support structure, this is a genuine differentiator worth weighing against simpler, medication-focused alternatives that rely on a single dedicated provider throughout your treatment.
The tradeoff is that coordinating with multiple team members can sometimes mean less continuity than working with a single dedicated provider, and it's worth asking directly during your evaluation how the team-based model actually works in practice — who you'll primarily communicate with for day-to-day questions, and how dose adjustments and side-effect management are handled across the team, since fragmented communication can sometimes slow down responses to time-sensitive questions.
Found's Background and Regulatory Standing
Found has operated in the GLP-1 telehealth space since 2020, giving it a moderate track record relative to some newer entrants and less than some of the longer-established names like Ro. As with any provider in this space, it's worth checking current regulatory standing directly — whether Found has received any FDA warning letters, and what specific compounding pharmacy partnerships it currently maintains — since this information can change and isn't always reflected accurately in older reviews or outdated comparison articles that may no longer describe the company's current operations.
Found has also gone through some public reporting around internal restructuring and leadership changes over the past few years, which is worth being aware of as general background context, though it doesn't necessarily reflect on current clinical service quality directly. As always, checking the most recent available information directly with the company is more reliable than relying on older articles when evaluating a fast-changing industry like this one specifically.
Who Found Fits Best
Found's multi-tier structure and team-based approach make it a reasonable fit for a specific type of patient, though the added complexity of navigating multiple tiers may not suit every patient equally well, particularly those who prefer simplicity above all else.
- Want structured behavioral coaching and community support built in
- Value having both compounded and brand-name medication options under one platform
- Are comfortable navigating a multi-tier plan structure to find your best fit
- Want a single, easy-to-compare flat price for GLP-1 treatment
- Don't need built-in behavioral coaching or community features
- Prefer knowing your exact monthly cost without cross-referencing plan tiers
One plan.
One flat price.
Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included, no tiers to compare.
Get Started → Or start your free health assessmentFrequently Asked Questions
Found typically offers a compounded GLP-1 plan, a branded GLP-1 plan (billed separately via insurance or cash pay), and a non-GLP-1 generics plan, each with different billing structures.
Generally no. Lab testing, when required by your provider, is typically billed separately from the membership fee at a Quest or Labcorp location, or through an at-home kit.
Yes. Found works with board-certified clinicians trained in obesity medicine and offers both FDA-approved brand-name medications and compounded alternatives depending on eligibility.
Because Found segments its offering into multiple plan families with different billing structures (compounded, branded, generic), understanding your true total cost requires knowing which specific plan applies to your situation, rather than a single universal price.
Yes. Found offers options like metformin, bupropion-naltrexone, and other non-GLP-1 medications for patients who aren't eligible for or don't want a GLP-1 medication.
Yes, generally. Luma Health's single flat price ($197/month semaglutide, $297/month tirzepatide) doesn't require navigating multiple plan tiers to understand your total monthly cost.
This is determined based on your health profile and goals during your initial evaluation. Ask directly during signup which specific tier applies to you, since pricing varies significantly by tier.
Yes, Found includes non-GLP-1 tiers with behavioral coaching and other tools for patients in that situation, which is a genuine flexibility advantage over GLP-1-only providers.
It depends on whether you'll actually use it consistently. Unused coaching features add cost without adding benefit, regardless of how well-designed the program is, so consider your own history with similar tools before assuming it's worth the premium.
Yes, Found has operated in the GLP-1 telehealth space since 2020 and works with licensed U.S. providers. As with any provider, verify current regulatory standing and compounding pharmacy partnerships directly before enrolling.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov